RegeneRx has join hands with the U.S. Army Medical Research Institute of Chemical Defense and Gabriel Sosne, MD, associate professor of ophthalmology at Wayne State University, to evaluate the ability of its eye drop formulation of Tß4 for preventing or reducing damage to the eye caused by exposure to chemical agents.
Over the next year, the partnership plans to conduct a series of research experiments with the drug, called, RGN-259.
RegeneRx is developing the the drug called RGN-259, for treating ophthalmic wounds and related disorders. The drug already shows success in treating non-healing eye ulcers of keratitis patients.
RGN-259 was applied to corneal ulcers that had not healed for at least 6 weeks and for up to several months. By treatment day 28, eye ulcers had either healed completely or demonstrated significant improvement in all four patients, according to the release.
Thirty days after the treatment, ulcers had completely healed or remained healed; those that had demonstrated significant improvement continued to improve after treatment had ended.
RGN-259 was well-tolerated with no drug-related adverse events.
J.J. Finkelstein, president and chief executive officer of RegeneRx, believes that their technology will successfully pass the testing of US army. RegeneRx is prepared to assist in any way possible to support efforts to protect the eyes of military personnel and citizens from exposure to debilitating or life-threatening chemical agents.
RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively.
These product candidates are based on TB4, a synthetic copy of a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to its products and has sponsored four Phase II dermal and ophthalmic clinical trials and a Phase I parenteral (injectable) clinical trial supporting systemic delivery of RGN-352 for acute cardiovascular indications.
Source: OSNSuperSite
Filed under Americas, Eye Care Program, Eye Treatment, Featured Article, Improved Vision | Tags: eye, Keratitis, ophthalmic wound healing drug, Ophthalmology, RGN-259 | Comment Below
Related?
Amritsar — The City Known for Ophthalmologists October 14th, 2006 For more than a century Amritsar has produced noted eye surgeons, both form the Royal British Army as well as from our own. The holy city is also called the ‘Mecca’ for treatment of eye ailments’.
Now, drug-delivering contact lensesJuly 22nd, 2009 WASHINGTON - Glaucoma patients and dry-eye sufferers may soon be able to trade their messy eye drops for a contact lens that delivers medication gradually over time, say scientists. Medication through eye drops tends to be highly ineffective, not because the drugs are impotent, but because of the body's own natural defences.
FDA Proposes Improving Contact Lens Product Testing and Advocating Universal Lens-care GuidelinesJune 25th, 2008 At the US Food and Drug Administration meeting in Washington last week, the eye experts have recommended some improved contact lens product testing. They also advocated universal lens-care guidelines to improve contact lens safety.
Organ donation by octogenarian woman helps three liveJanuary 27th, 2009 NEW DELHI - An octogenarian woman has become one of the oldest organ donors in the country as her family consented to donate her liver and cornea following her death, officials here said Wednesday. Gyan Kaur, 82, died Tuesday.
FDA says Ista Pharmaceuticals' eye drug Bepreve did not show serious adverse effects in testsJune 24th, 2009 FDA says Ista eye drug has no serious side effectsWASHINGTON — Federal health scientists said Wednesday an anti-itching drug from eye care company Ista Pharmaceuticals did not show any serious side effects in testing on patients. Ista is asking the Food and Drug Administration to approve its formula Bepreve to relieve itchiness caused by seasonal allergies.
New sutureless eye surgery promises less postoperative risk with quicker recoveryOctober 29th, 2008 Latest news reveals about nearly 80 successful operations that has been carried by a new special surgery named sutureless eye surgery. This surgery with its unique instruments has a specialty of healing wounds much more faster than that of conventional type.
Pfizer with Bausch & Lomb to promote Ophthalmic drugs in USMarch 6th, 2009 Drug developer Pfizer Inc. announced on Tuesday that they have tide up with a five year deal with Bausch & Lomb- to co-promote prescription eye-care drugs in the United States of America.
Indian eye hospital launched bladeless Zyoptix lasik technology for corneal surgeryJanuary 19th, 2009 Lotus Eye Care Hospital (Coimbatore, India) launched this 1.5 crore equipment to treat conical cornea and corneal transplant with a 100-percent blade-free technology. It is a fully integrated personalized correction system that helps patients achieves better quality vision.
